Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in Relapsed or Refractory Peripheral T-cell Lymphoma
NCT05833724Phase 2Recruiting
- Sponsor
- GNT Biotech & Medicals
- Start
- Oct 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by GNT Biotech & Medicals. Primary endpoint: Objective Response Rate at 24 months. Started Oct 2024; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05833724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05833724.